• MicroRNA as diagnostic biomarkers of liver damage at Epstein-Barr viral hepatitis in children
To content

MicroRNA as diagnostic biomarkers of liver damage at Epstein-Barr viral hepatitis in children

SOVREMENNAYA PEDIATRIYA. 2015.1(65):115-119; doi 10.15574/SP.2015.65.115


MicroRNA as diagnostic biomarkers of liver damage at Epstein-Barr viral hepatitis in children


Shadrin V. O., Dosenko V. E.

A.A. Bogomolets National Medical University, Kyiv, Ukraine

A.A. Bogomolets Institute of Physiology of the NAMS of Ukraine, Kiev


Objective. To assess the level of miRNA- 21-3p and miRNA 885-5p in the serum of children with hepatitis of EBV-etiology.


Patients and methods. The results of clinical, laboratory and instrumental studies of 23 children with hepatitis of EBV-etiology are analyzed. Indicators of children with EBV_hepatitis were compared with the rates of 20 healthy children of the same age. A set of studies included the analysis of anamnestic data, clinical and preclinical data. Diagnosis of viral EBV hepatitis was carried out on the base of ELISA detection of specific antibodies to the M and G class virus, EBV DNA in in the blood saliva and by PCR method. The degree of inflammatory activity was determined by the level of transaminases (ALT and AST). The level of miRNA-2-3p and miRNA-885-5p in the blood serum was determined by the method of TaqMan.


Results. A significant increase of miRNA-21-3p in the blood serum of children with EBV-hepatitis: 21.8375 (1.1439; 2046.25) CU against 0.6516 (0.0133, 5.3708) CU in the group of healthy children (p<0.05). The content of miRNA-885-5p had no significant difference from the data of the control group and was 1.0248 (0.0342, 14.5261) CU against 0.1801 (0.0122, 1.5653) CU.


Conclusions. Identified changes in the content of miRNA-21-3p and miRNA-885-5p in children with EBV-hepatitis indicate the possibility of use of miRNA-21-3p as a diagnostic marker of liver injury during the EBV-infection.


Key words: microRNA, Epstein-Barr virus, hepatitis, children.



1. Учайкин ВФ, Смирнов АВ, Чуелов СБ, Россина АЛ. 2012. Герпесвирусные гепатиты у детей. Педиатрия. 91;3: 136—142.

2. Desmet V, Gerber M, Hoofnagle JH et al. 1995. Классификация хронического гепатита: диагностика, определение степени тяжести и стадии течения. Рос журн гастроэнтерол, гепатол, колопроктол. 2: 38—45.

3. Cовременные критерии диагностики и подходы к лечению хронического гепатита у детей.Метод реком. К. 2010: 41.

4. Хмилевская СА, Зайцева ИА, Михайлова ЕВ. 2009. Изменение функционального состояния печени при Эпштейна-Барр вирусном мононуклеозе у детей. Саратовский научн-мед журн. 5;4: 572—577.

5. Шерлок Ш, Дули Дж. 1999. Заболевания печени и желчных путей. Практич рук-во. Пер с англ. Под ред. ЗГ Апросиной, НА Мухиной. М, ГЭОТАР МЕДИЦИНА: 864.

6. Учайкин ВФ, Смирнов АВ, Чуелов СБ и др. 2008. Эпштейна—Барр вирусный гепатит у детей. Актуальные вопросы детской патологии и вакцинопрофилактики у детей. Матер конгр. СПб, Спец лит: 148.

7. Castro RE, Ferreira DM, Zhang X et al. 2010. Am J Physiol Gastrointest Liver Physiol. 229(4): 887—897.

8. Bala S, Petrasek J, Mundkur S et al. 2012. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 56: 1946—1957.

9. Blanco-Calvo M, Calvo L, Figueroa A et al. 2012. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel). 12: 9349—9362

10. Cermelli S, Ruggieri A, Marrero JA. 2011. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937.

11. Marquez RT, Bandyopadhyay S, Wendlandt EB et al. 2010. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest. 90: 1727—1736.

12. Winter TN, Bang-Berthelsen CH, Heiberg IL et al. 2013. Differential plasma MicroRNK Profiles in HBeAg Positive and HBeAg Negative Children with Cronic Hepatitis B. PLOS ONE. 8, Is 3: 58236.

13. Gao B, Bataller R. 2011. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 141: 1572—1585.

14. Shu J, Kren BT, Xia Z et al. 2011. Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology. 54: 609—619.

15. Kwiecinski M, Noetel A, Elfimova N et al. 2011. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One. 6: e24568.

16. Ji J, Shi J, Budhu A et al. 2009. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 361: 1437—1447.

17. Roderburg C, Urban GW, Bettermann K et al. 2011. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 53: 209—218.

18. Meng F, Henson R, Wehbe-Janek H et al. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133: 647—658.

19. Li ZY, Xi Y, Zhu WN et al. 2011. Positive regulation of hepatic miR-122 expression by HNF4alpha. J Hepatol. 55: 602—611.

20. Gui J, Tian Y, Wen X et al. 2011. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 120: 183—193.

21. Sekiya Y, Ogawa T, Yoshizato K et al. 2011. Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun. 412: 74—79.

22. Zaret KS. 2002. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet. 3: 499—512.